WINTON GROUP Ltd Decreases Stock Position in Encompass Health Corporation $EHC

Key Points

• WINTON GROUP Ltd cut its Encompass Health position by 93.8% in the second quarter, selling 31,800 shares and retaining 2,100 shares worth approximately $212,000. Institutional investors collectively own 97.25% of the company.
• Encompass Health reported quarterly EPS of $1.55, beating estimates by $0.07, while revenue rose 9.6% year over year to $1.60 billion. The company also raised its quarterly dividend from $0.19 to $0.21 per share.
• Despite recent insider selling, analysts maintain a consensus “Buy” rating, with an average price target of $148.20 versus the reported share price of $121.84.

WINTON GROUP Ltd trimmed its holdings in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 93.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,100 shares of the company's stock after selling 31,800 shares during the period. WINTON GROUP Ltd's holdings in Encompass Health were worth $212,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Transamerica Financial Advisors LLC bought a new stake in Encompass Health in the 2nd quarter worth about $29,000. Persistent Asset Partners Ltd purchased a new stake in shares of Encompass Health during the 2nd quarter valued at about $36,000. Keating Financial Advisory Services Inc. bought a new stake in shares of Encompass Health in the second quarter worth approximately $39,000. Assetmark Inc. raised its holdings in shares of Encompass Health by 89.6% during the first quarter. Assetmark Inc. now owns 455 shares of the company's stock valued at $44,000 after purchasing an additional 215 shares during the last quarter. Finally, Covestor Ltd lifted its position in Encompass Health by 24.4% during the fourth quarter. Covestor Ltd now owns 540 shares of the company's stock valued at $57,000 after purchasing an additional 106 shares during the period. Institutional investors own 97.25% of the company's stock.

Encompass Health Price Performance

Shares of Encompass Health stock opened at $121.84 on Friday. The stock has a market cap of $12.02 billion, a P/E ratio of 19.84, a P/E/G ratio of 2.49 and a beta of 0.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.19 and a current ratio of 1.19. The stock's fifty day moving average is $118.44 and its 200 day moving average is $108.60. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. Encompass Health's revenue for the quarter was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Sell-side analysts anticipate that Encompass Health Corporation will post 6.08 earnings per share for the current year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.21 dividend. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $0.84 dividend on an annualized basis and a yield of 0.7%. This is a boost from Encompass Health's previous quarterly dividend of $0.19. Encompass Health's payout ratio is presently 12.38%.

Insiders Place Their Bets

In related news, EVP John Darby sold 8,906 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.95, for a total value of $1,121,710.70. Following the sale, the executive vice president directly owned 75,041 shares in the company, valued at approximately $9,451,413.95. The trade was a 10.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mark Tarr sold 173,148 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $125.47, for a total value of $21,724,879.56. Following the transaction, the chief executive officer owned 267,814 shares of the company's stock, valued at $33,602,622.58. This represents a 39.27% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 186,912 shares of company stock valued at $23,434,845. 1.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on EHC shares. Leerink Partners set a $152.00 target price on shares of Encompass Health in a report on Friday, May 22nd. TD Cowen increased their price target on Encompass Health from $125.00 to $140.00 and gave the company a "buy" rating in a report on Monday, August 10th. UBS Group raised their price target on Encompass Health from $150.00 to $155.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Barclays lifted their price objective on Encompass Health from $140.00 to $144.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Truist Financial increased their target price on Encompass Health from $140.00 to $150.00 and gave the company a "buy" rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $148.20.

Encompass Health Profile

Encompass Health Corporation NYSE: EHC is a provider of post-acute healthcare services in the United States. The company operates inpatient rehabilitation hospitals that care for patients recovering from illness, injury, surgery or other medical conditions requiring intensive rehabilitation.

Its rehabilitation programs commonly serve patients recovering from strokes, brain and spinal cord injuries, neurological disorders, cardiac and pulmonary conditions, hip fractures, amputations and other orthopedic conditions.

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Corporation (NYSE:EHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.